The Biden administration wants to increase access to and affordability of the overdose reversal drug naloxone as part of its broader strategy to address the opioid overdose epidemic, but the administration’s plan is focused more on ensuring consistent access across states and makes no mention of switching the drug from prescription to over-the-counter status. Lawmakers, medical groups and harm reduction experts have called for FDA and the Biden administration to switch naloxone from prescription to OTC status since manufacturers have...